3 minute read
Apr. 19, 2022

An Oral CDK5-Mediated PPARγ Phosphorylation Inhibitor

compound 10

oral PPARg phosphorylation inhibitor, partial agonist efficacy in diabetic mouse model from structure-based virtual screen ACS Med. Chem. Lett., March 11, 2022 AstraZeneca, Gothenburg, SE

drughunter.com
Drug Hunter Team
Reviewer:  

“ Compound 10” (AstraZeneca) is an oral CDK5-mediated PPARγ phosphorylation inhibitor and partial PPARγ agonist being developed as an antidiabetic drug . Although widely used PPARγ agonists such as rosiglitazone and pioglitazone are effective antidiabetics, they are limited by their side effects which have been attributed to PPARγ [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in